Source: pixabay.com
FDA Lifts Clinical Hold on LB-001 IND for Methylmalonic Acidemia
During the Phase 1/2 SUNRISE clinical trial, which evaluated LB-001 for pediatric patients with methylmalonic acidemia, at least two participants experienced serious and severe adverse reactions: thrombotic microangiopathy. While investigating…
Continue Reading
FDA Lifts Clinical Hold on LB-001 IND for Methylmalonic Acidemia
